Nurix Therapeutics, Inc. 4

Chief Legal Officer Christine Ring exercised 3,422 Nurix Therapeutics stock options at $1.86 and sold 8,148 common shares at about $16.60 on June 2, 2026 under a Rule 10b5-1 plan.

On June 2, 2026, Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised 3,422 stock options with a $1.86 exercise price, acquiring an equivalent number of common shares, and immediately sold 8,148 common shares at a weighted average price of $16.5995 pursuant to a pre-arranged Rule 10b5-1 trading plan, resulting in 13,579 shares of common stock held directly after the transactions. The option exercise was from a fully vested employee stock option grant that originally vested over time, and the sale appears to be a liquidity or diversification transaction rather than a new open‑market purchase. Based on the sale price, the sale transaction was materially larger in value than the option exercise cost, and the remaining equity position reflects ongoing ownership alignment with shareholders.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

sec

Accession

0001817199-26-000020

Alert Tier

6